HHS announces prohibitions against discriminating by sexual orientation, gender identity in health care; updated CDC guidance highlights airborne threat of COVID-19; European Union, Pfizer/BioNTech agree to deal that could reach 1.8 billion vaccine doses.
HHS announced Monday that discrimination based on sexual orientation and gender identity will be protected by sex discrimination laws Section 1557 and Title IX’s prohibitions. The Office of Civil Rights will enforce the new legislative updates, which were said to be made in light of the Supreme Court’s decision in Bostock v. Clayton County. Reversing former President Donald Trump’s ban on LGBTQ health protections, it will now be prohibited to discriminate against consumers on the basis of sexual orientation or gender identity.
Reported by The New York Times, updated public guidance issued by the CDC this past Friday on how the coronavirus spreads emphasized the occurrence of airborne transmission, which differs from prior guidance that suggested close contact was the primary cause of infection. The CDC notes that COVID-19 can be spread by inhaling very fine respiratory droplets and aerosolized particles, as well as contact with contaminated surfaces to one’s mouth, nose, or eyes. Noting that the virus can be inhaled even when more than 6 feet apart, the new focus underscores the need for the federal Occupational Safety and Health Administration to enact preventive standards for employers who wish to return employees to on-site workspaces.
As the European Union (EU) decided not to renew its current COVID-19 vaccine contracts with Johnson & Johnson and AstraZeneca, the EU Commission announced a substantial contact extension with Pfizer/BioNTech to produce potentially 1.8 billion doses of its vaccine through 2023. Reported by the Associated Press, EU Commission President Ursula von der Leyen said that the approved contract is guaranteed for 900 million doses, which can double through a future option.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More